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droindole-2-carboxylic acid) is a long-acting angiotensin-
converting enzyme (ACE) inhibitor which is effective in 
reducing blood pressure and improving outcomes in a num-
ber of cardiovascular diseases [1]. Perindopril is a prodrug 
ester which was observed to convert to diacid perindoprilat, 
an active metabolite, during in vivo studies [2]. Currently, 
two salts of perindopril, erbutamine (tert-butylamine) and 
l-arginine, are used therapeutically [3]. Both salts are 
chemically unstable and undergo degradation in dosage 
forms to other diacids and diketopiperazines [4]. Perin-
dopril l-arginine is the first ACE inhibitor analog which 
contains only a stereoselective S enantiomers. Due to the 
presence of a double bond in the tertiary amide bond of the 
C-terminal proline containing a peptide bond, perindopril 
can exist in the form of cis/trans isomers (Fig. 1).
Only several HPLC-DAD methods have been reported 
for the determination of perindopril in the presence of its 
degradation products and synthesis-induced impurities [5, 
6]. Since combinations of perindopril with drugs from other 
groups such as calcium channel blockers or diuretics are 
used in hypertension therapies, HPLC-DAD methods for the 
determination of perindopril in the presence of other drugs 
in pharmaceutical preparations and in body fluids have been 
reported as well [7, 8]. Chromatographic techniques have 
also been applied to investigate separation between the cis 
and trans isomers of perindopril. Stability studies of perin-
dopril supported by a theoretical approach showed that the 
Abstract A stability-indicating ultra-high-performance 
liquid chromatography (UHPLC) method with a diode 
array detector was developed and validated for the determi-
nation of cis/trans isomers of perindopril l-arginine in bulk 
substance and pharmaceutical dosage form. The separa-
tion was achieved on a Poroshell 120 Hilic (4.6 × 150 mm, 
2.7 µm) column using a mobile phase composed of ace-
tonitrile–0.1 % formic acid (20:80 v/v) at a flow rate of 
1 mL min−1. The injection volume was 5.0 µL and the 
wavelength of detection was controlled at 230 nm. The 
selectivity of the UHPLC-DAD method was confirmed by 
determining perindopril l-arginine in the presence of deg-
radation products formed during acid–base hydrolysis and 
oxidation as well as degradation in the solid state, at an 
increased relative air humidity and in dry air. The method’s 
linearity was investigated in the ranges 0.40–1.40 µg mL−1 
for isomer I and 0.40–2.40 µg mL−1 for isomer II of perin-
dopril l-arginine. The UHPLC-DAD method met the preci-
sion and accuracy criteria for the determination of the iso-
mers of perindopril l-arginine. The limits of detection and 
quantitation were 0.1503 and 0.4555 µg mL−1 for isomer I 
and 0.0356 and 0.1078 µg mL−1 for isomer II, respectively.
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type of salt and the compound charge have an impact on its 
degradation, proving perindopril l-arginine to be more sta-
ble than erbutamine salt [9, 10]. No procedures based on 
UHPLC solutions for the determination of perindopril have 
been reported. However, the application of UHPLC method 
in perindopril determination, with reduction of analysis time 
with the possibility of a reliable separation of its isomers, 
meets the criteria of modern analytical techniques.
Therefore, the aim of our study was to develop a 
UHPLC-DAD method allowing separation of the cis and 
trans isomers in bulk substances and pharmaceutical dos-
age forms (Prestarium®), and to investigate their degrada-
tion under the influence of stress factors.
Experimental
Chemicals, Reagents, and Solutions
Perindopril l-arginine (purity >98 %) in bulk substance was 
applied by India PVT LTD., while Prestarium®, containing 
racemic mixture of cis/trans isomers (10 mg coated tablets), 
was a commercial preparation manufactured by Servier. 
Hydrochloric acid, sodium hydroxide solution, hydrogen 
peroxide and all other chemicals were obtained from P.O.Ch. 
(Gliwice, Poland). Acetonitrile of an HPLC grade was sup-
plied by Merck KGaA (Darmstadt, Germany) and formic 
acid (100 %) by P.O.Ch. (Gliwice, Poland). Ultrapure water 
(18 MΩ cm at 25 °C) was prepared using an Exil SA 67120 
Millipore purification system (Molsheim, France).
Chromatographic Equipment
The LC system (Dionex Thermoline Fisher Scientific, 
Schwerte, Germany) was equipped with a high pressure 
pump (UltiMate 3000), an autosampler (UltiMate 3000) 
and a DAD detector (UltiMate 3000). For data process-
ing and acquisition, Chromeleon software version 7.0 from 
Dionex Thermoline Fisher Scientific (US) was used. As 
the stationary phase, a Poroshell 120 Hilic column, 2.7 µm 
particle size, 4.6 × 150 mm (containing ultra-high purity sil-
ica, 99.995 % SiO2) (Agilent Technology, Santa Clara, US) 
was used. The mobile phase consisted of acetonitrile–0.1 % 
formic acid (20:80 v/v). The flow rate of the mobile phase 
was 1.0 mL min−1. The wavelength of the UV detector was 
set at 230 nm. The injection volume was 5.0 µL. The column 
temperature was 25 °C. Chromatographic separation was 
performed with a pressure of 420 bars. PH of mobile phase 
was measured by pH-meter (Mettler Toledo SevenCompact 
pH/Ion S220, Warsaw, Poland).
Method Validation
The method was validated according to the International 
Conference on Harmonization Guidelines [11]. It com-
prised selectivity, linearity, accuracy, precision, limits of 
detection (LOD) and quantitation (LOQ). All measure-
ments were performed in triplicates.
Sample Solutions
Sample solution of perindopril l-arginine was prepared by 
dissolving 10.0 mg of perindopril l-arginine in 25.0 mL 
of ultrapure water. Prestarium®, commercially available 
dosage form of perindopril l-arginine, was pounded and 
weighed mass of the appropriate 10.0 mg of perindopril 
l-arginine and dissolved in 25.0 mL of ultrapure water.
Selectivity
The selectivity of determination of perindopril l-arginine 
was examined for non-degraded and degraded samples. 
The selectivity of perindopril l-arginine determination was 
established in the presence of excipients (lactose monohy-
drate, magnesium stearate). While the selectivity of perin-
dopril l-arginine determination in degraded samples was 
examined in the presence of degradation products formed 
during acidic–basic hydrolysis (in hydrochloric acid (1 M) 
at 353 K and in solution of sodium hydroxide (1 M) at 














Fig. 1  Chemical structure of cis/trans isomers of perindopril
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(at an increased relative air humidity 76.4 % RH at 353 K 
and in dry air 0 % RH at 373 K).
Precision
Precision of the assay was determined in relation to repeat-
ability (intra-day) and intermediate precision (inter-day) at 
three levels of concentration: 80 % (1.6 µg mL−1), 100 % 
(2.0 µg mL−1) and 120 % (2.4 µg mL−1). Every sample was 
injected six times.
Accuracy
The accuracy of the method was determined by recovering 
perindopril l-arginine from placebo. As placebo substance 
was chosen talc. The accuracy was established at three lev-
els 80, 100 and 120 % of label claim of the substance for 
determination of perindopril l-arginine in bulk substance 
and in pharmaceutical dosage form.
The Limit of Detection (LOD) and Quantification (LOQ)
LOD and LOQ parameters were determined from the 
regression equations of perindopril l-arginine. LOD = 3.3 
Sy/a, LOQ = 10 Sy/a; where Sy is a standard error and a is 
the slope of the corresponding calibration curve.
Robustness
The impact of the percentage of acetonitrile in the mobile 
phase, pH of mobile phase, the flow rate and the column 
temperature on the peak area and shape of perindopril 
l-arginine were determined.
Standard Solution
Standard stock solution of perindopril l-arginine was pre-
pared by dissolving 10.0 mg of perindopril l-arginine in 
25.0 mL of ultrapure water. Standard stock solution was 
kept during period of studies.
Results and Discussion
The UHPLC procedure was optimized with a view to 
developing a method for stability-indicating assay of per-
indopril l-arginine and separation of its cis and trans iso-
mers in bulk substance and pharmaceutical dosage form. 
Under the optimized chromatographic conditions, two 
peaks for non-degraded samples of perindopril l-arginine 
were recorded. As shown by the chromatograms, isomers 
I and II of perindopril l-arginine were eluted at retention 
times tR = 1.76 and tR = 1.95, respectively (Fig. 2a). On 
Fig. 2  The chromatogram of isomer I (tR = 1.763 min) and isomer 
II (tR = 1.950 min) of perindopril l-arginine: in bulk substance (a); 
in pharmaceutical dosage form Prestarium® (b); in degraded samples 
in HCl (1 M, T = 353 K, content of initial concentration 39 %) (c); in 
degraded samples in NaOH (1 M, T = 353 K, content of initial con-
centration 33 %) (d)
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the chromatograms of the degraded samples of perindopril 
l-arginine a decrease was observed in the peaks of the iso-
mers and the appearance of peaks related to the degradation 
products was registered. The spectrophotometric purities of 
peaks of main substance in the presence of its degradation 
products were confirmed. Perindopril l-arginine was sub-
jected to acidic, basic, thermal, photolytic, and oxidative 
stress conditions according to ICH regulations. Different 
rates of degradation were observed for the isomers depend-
ing on the stress factors applied. The peak tailing factors 
for the isomers of perindopril l-arginine were between 
1.37 and 1.64. The chromatograms of non-degraded and 
degraded samples of perindopril l-arginine are shown in 
Fig. 2a–d. In a previous investigation, Bouabdallah et al. 
[5] confirmed the effect of organic solvent, pH, tempera-
ture, β-cyclodextrins and flow rate on the possibility of 
separating the cis/trans isomers of perindopril l-arginine 
when the chromatographic procedure was based on a col-
umn with 5 μm particle size. The isomers of perindopril 
l-arginine were eluted at 2.14 and 3.88 min. However, the 
isomers of perindopril l-arginine were better separated and 
in a shorter time when the UHPLC-DAD method described 
in the present work was applied.
The method was validated for selectivity, linearity, inter- 
and intra-day accuracy and precision, robustness, system 
suitability, LOD, LOQ and recovery for the assay of per-
indopril l-arginine in the pharmaceutical preparation Pre-
starium®. All validation parameters were established for 
the cis/trans isomers of perindopril l-arginine. The calibra-
tion plots were linear in concentration of isomer I in the 
range 0.40–1.40 µg mL−1 (n = 11, r = 0.9914) and iso-
mer II 0.40–2.40 µg mL−1 (n = 11, r = 0.9998). They were 
described by the equations y = ax: y = (0.2143 ± 0.0394)x 
for isomer I and y = (1.7652 ± 0.0266)x for isomer II. The 
b values, calculated from the equation y = ax + b, were 
insignificant because of being lower than the critical value 
tb = b/Sb (Table 1). The values of RSD for the determina-
tion of the isomers during the evaluation of intra-day preci-
sion ranged from 0.89 to 1.91 % for isomer I and from 1.06 
to 1.98 % for isomer II. The ranges of inter-day determina-
tion were 1.04–1.71 and 1.20–1.80 % for isomers I and II, 
respectively. The accuracy of determination, established at 
80, 100 and 120 % of the label claim, was in the ranges 
95.56–96.27 % for isomer I and 97.10–97.89 % for isomer 
II. The LOD and LOQ for isomer I of perindopril l-argi-
nine were 0.1503 and 0.4555 µg mL−1 while those for iso-
mer II 0.0356 and 0.1078 µg mL−1, respectively.
The best separation of the cis/trans isomers of perindo-
pril l-arginine was obtained for the above-mentioned chro-
matographic parameters. The robustness of the UHPLC-
DAD procedure was evaluated after changing the mobile 
phase composition (acetonitrile volume, 20 ± 5 v/v), 
mobile phase pH (formic acid concentration, 3–0.05 %), 
flow rate (1.0 ± 0.1 mL min−1), absorption wavelength 
(353 ± 3 nm) and column temperature (25 ± 10 °C). No 
statistically significant differences were established for 
the parameters studied in the investigation of robustness 
as their deviation did not exceed the permissible range of 
±2 %. While higher changes in these parameters resulted 
in the lack of separation of the isomers and the appearance 
of tailing peaks. System suitability was examined in regard 
to the relative standard deviation for peak areas and peak 
times, peak resolution, peak asymmetry and the number of 
theoretical plates. All parameters are collected in Table 2.
Conclusion
Since the UHPLC-DAD method presented in this com-
munication is a simple, accurate, selective and time-saving 
tool for the determination of the cis/trans isomers of per-
indopril l-arginine, which also allows good separation, 
it can be used for routine testing and stability analysis of 
that compound. In addition, the method was validated for 
compliance with ICH guidelines and proved to meet the 
acceptance criteria. It may, therefore, be recommended for 
Table 1  Validation parameters of linearity of isomer I and isomer II 
of perindopril l-arginine
Sa standard deviation of slope, Sb standard deviation of intercept, t, 
calculated values of Student’s t test, tα,f = 2.1709 critical values of 
Student’s test for degrees of freedom f = 11 and significance level 
α = 0.05
Isomer I Isomer II
Retention time (min) 1.76 1.95
Range of linearity (µg mL−1) 0.40–1.40 0.40–2.40
Regression equation (y)
 Slope (a ± Sa) 0.21 ± 0.04 1.77 ± 0.03
  Intercept (b ± Sb) 0.02 ± 0.04 0.01 ± 0.04
 LOD (µg mL−1) 0.1503 0.0356
 LOQ (µg mL−1) 0.4555 0.1078
 Correlation coefficient (r) 0.9914 0.9998
Table 2  System suitability tests of the UHPLC-DAD
Resolutions were calculated between two adjacent peaks in no-
degraded and degraded samples
Parameter Isomer I Isomer II
Relative standard deviation of peak area % 1.84 1.50




Asymmetry (tailing factor) 1.83 1.51
Number of theoretical plates 34,693 28,716
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quality evaluation of perindopril l-arginine in the commer-
cial product Prestarium®, including determination of its 
cis/trans isomers.
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